A case of effective disease control of advanced gastric cancer following ramucirumab plus FOLFIRI in second line treatment in clinical practice
Ramucirumab is a human anti-vascular endothelial growth factor receptor 2(VEGFR-2)monoclonal antibodythat acts on vascular endothelial cells to inhibit angiogenesis. Ramucirumab in monotherapy or in combination with paclitaxel or FOLFIRI has proven to prolong overall survival in patients with pretre...
Shranjeno v:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Russo |
| Izdano: |
Remedium Group LLC
2020-12-01
|
| Serija: | Медицинский совет |
| Teme: | |
| Online dostop: | https://www.med-sovet.pro/jour/article/view/5957 |
| Oznake: |
Brez oznak, prvi označite!
|